Notices

- **Notice of NIA Participation in PA-18-343: "Academic Research Enhancement Award (R15 Clinical Trial Required)"**
  (NOT-AG-18-005)
  National Institute on Aging

- **Notice of NIA Participation in PA-18-676: "Research on the Health of Women of Understudied, Underrepresented and Underreported (U3) Populations An ORWH FY18 Administrative Supplement (Admin Supp Clinical Trial Optional)"**
  (NOT-AG-18-007)
  National Institute on Aging

- **Notice of NCI's Participation on PA-18-498, End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness (R01 Clinical Trial Optional)**
  (NOT-CA-18-032)
  National Cancer Institute

- **Notice of NCI's participation on PA-18-499, End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness (R21 Clinical Trial Optional)**
  (NOT-CA-18-033)
  National Cancer Institute

- **Notice of Change to PAR-17-233 "Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts (U01)"**
  (NOT-CA-18-055)
  National Cancer Institute

- **Notice of Correction to the Specific Research Objectives for PA-16-175 Exploratory Grants in Cancer Epidemiology and Genomics Research (R21)"**
  (NOT-CA-18-057)
  National Cancer Institute

- **Notice of Change in Eligibility of Foreign Components and Revision of Award Budget for PAR-18-103 "Limited Competition: Small Grant Program for NIDDK K01/K08/K23 Recipients (R03 Clinical Trial Optional)"**
  (NOT-DK-18-011)
  National Institute of Diabetes and Digestive and Kidney Diseases

- **Notice to Clarify the Types of Clinical Trials NIBIB Will Support Under PA-18-048 Zika Virus (ZIKV) Complications (R21 Clinical Trial Optional)**
  (NOT-EB-18-007)
  National Institute of Biomedical Imaging and Bioengineering
- **Notice of Change to Expiration Date on BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed)**
  (NOT-EB-18-012)
  National Institute of Biomedical Imaging and Bioengineering

- **Notice of Technical Assistance Webinar for RFA-HL-19-014: Stimulating T4 Implementation Research to Optimize Integration of Proven-effective Interventions for Heart, Lung, and Blood Diseases and Sleep Disorders into Practice (STIMULATE)**
  (NOT-HL-18-605)
  National Heart, Lung, and Blood Institute

- **Revision: Notice of Correction to Application Instructions in RFA-HL-19-008: Limited Competition: Clinical Research Sites for the MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS) (U01 Clinical Trial Not Allowed)**
  (NOT-HL-18-609)
  National Heart, Lung, and Blood Institute
  National Cancer Institute
  National Human Genome Research Institute
  National Institute on Aging
  National Institute of Allergy and Infectious Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  National Institute of Nursing Research

- **Notice of NIMH Participation in PA-18-488 "NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)"**
  (NOT-MH-18-025)
  National Institute of Mental Health

- **Notice of Changes in the Eligibility of Candidates Supported by the NIMH Administrative Supplement Program to Enable Continuity of Research Experiences of MD/PhDs during Clinical training (Admin Supp)**
  (NOT-MH-18-029)
  National Institute of Mental Health

- **Notice of Change to RFA-MH-18-706, Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34- Clinical Trial Required)**
  (NOT-MH-18-030)
  National Institute of Mental Health

- **Notice of NINR's Participation in PA-18-271 Strengthening the HIV Pre-Exposure Prophylaxis (PrEP) Care Continuum through Behavioral, Social, and Implementation Science (R21 Clinical Trial Optional)**
  (NOT-NR-18-003)
  National Institute of Nursing Research
Notice of NINR's Participation in PA-18-281 Strengthening the HIV Pre-Exposure Prophylaxis (PrEP) Care Continuum through Behavioral, Social, and Implementation Science (R01 Clinical Trial Optional) (NOT-NR-18-004)
National Institute of Nursing Research

Notice of NINR's Participation in PA-18-272 Targeted basic behavioral and social science and intervention development for HIV prevention and care (R21 Clinical Trial Optional) (NOT-NR-18-005)
National Institute of Nursing Research

Notice of NINR's Participation in PA-18-273 Targeted basic behavioral and social science and intervention development for HIV prevention and care (R01 Clinical Trial Optional) (NOT-NR-18-006)
National Institute of Nursing Research

NINDS Notice to Clarify the Types of Clinical Trial Applications NINDS Will Support Under PA-18-159 "Mechanisms, Models, Measurement, & Management in Pain Research (R21 - Clinical Trial Optional)"
(NOT-NS-18-016)
National Institute of Neurological Disorders and Stroke

Notice of Intent to Publish a Funding Opportunity Announcement for BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) (NOT-NS-18-041)
National Institute of Neurological Disorders and Stroke
National Center for Complementary and Integrative Health
National Eye Institute
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Institute of Biomedical Imaging and Bioengineering
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Drug Abuse
National Institute on Deafness and Other Communication Disorders
National Institute of Mental Health

Notice of Correction of Earliest Start Date for RFA-RM-18-018 Somatic Cell Genome Editing Dissemination and Coordinating Center (U24 - Clinical Trial Not Allowed)"
(NOT-RM-18-016)
Office of Strategic Coordination (Common Fund)
Requests for Applications

- **Coordinating Center to Support NIDA Rural Opioid HIV and Comorbidity Initiative (U24 - Clinical Trial Not Allowed)**  
  (RFA-DA-19-004)  
  National Institute on Drug Abuse  
  Application Receipt Date(s): August 15, 2018, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates.

- **Bioequivalence of Topical Products: Elucidating the Thermodynamic and Functional Characteristics of Compositionally Different Topical Formulations (U01)**  
  (RFA-FD-18-010)  
  Food and Drug Administration  
  Application Receipt Date(s): May 19, 2018, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.

- **Renewal Applications: Centers of Excellence in Regulatory Science and Innovation**  
  (RFA-FD-18-011)  
  Food and Drug Administration  
  Application Receipt Date(s): June 4, 2018, by 11:59 PM Eastern Time.

- **Bioequivalence of Topical Products: Evaluating the Cutaneous Pharmacokinetics of Topical Drug Products Using Non-Invasive Techniques**  
  (RFA-FD-18-012)  
  Food and Drug Administration  
  Application Receipt Date(s): June 4, 2018, by 11:59 PM Eastern Time.

- **Computational fluid dynamics (CFD) and discrete element modeling (DEM) approach for predictions of dry powder inhaler (DPI) drug delivery**  
  (RFA-FD-18-014)  
  Food and Drug Administration  
  Application Receipt Date(s): May 29, 2018, by 11:59 PM Eastern Time.

- **Characterize skin physiology parameters utilized in dermal physiologically-based pharmacokinetic model development across different skin disease states**  
  (RFA-FD-18-017)  
  Food and Drug Administration  
  Application Receipt Date(s): May 29, 2018, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
• **Formulation drug product quality attributes in dermal physiologically-based pharmacokinetic models for topical dermatological drug products and transdermal delivery systems**
  (RFA-FD-18-019)
  Food and Drug Administration
  Application Receipt Date(s): May 28, 2018, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.

• **Three-Dimensional Approach for Modeling Nasal Mucociliary Clearance via Computational Fluid Dynamics (CFD)**
  (RFA-FD-18-020)
  Food and Drug Administration
  Application Receipt Date(s): June 4, 2018, by 11:59 PM Eastern Time.

• **Assuring Radiation Protection (U18)**
  (RFA-FD-18-021)
  Food and Drug Administration
  Application Receipt Date(s): June 4, 2018, by 11:59 PM Eastern Time.

**Program Announcements**

• **NIA Limited Competition: Renewals of, and Revisions to, Existing Alzheimer's Disease Patient Registry Cooperative Agreement Awards (U01 - Clinical Trial Not Allowed)**
  (PAR-18-715)
  National Institute on Aging
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

• **International Bioethics Research Training Program (D43 Clinical Trial Optional)**
  (PAR-18-716)
  John E. Fogarty International Center
  National Human Genome Research Institute
  Application Receipt Date(s): May 17, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Fogarty HIV Research Training Program for Low-and Middle-Income Country Institutions (D43 Clinical Trial Optional)
(PAR-18-717)
John E. Fogarty International Center
National Cancer Institute
National Institute on Alcohol Abuse and Alcoholism
National Institute on Drug Abuse
National Institute of Mental Health
Application Receipt Date(s): August 23, 2018, by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on this dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
You have received this information as a result of being subscribed to the UTHSCSA Office of Sponsored Programs fundinginfo2 ListServ. To remove yourself from this list, visit the Subscriber’s Corner in the List Archives http://lists.uthscsa.edu/scripts/wa.exe?A0=FUNDINGINFO2, and follow the onscreen instructions to log in and manage your list subscriptions.
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *